Product Information
LAMIVUDINE 300 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $1.4012 per EA under NDC 64380071104. Its NADAC has been published 361 times since Sep 12, 2018.
FDA first approved this application on Apr 19, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380071104
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA090457FDA Approved
4/19/2018
TE Code
AB
On Market Since
10/19/2018
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE 300 MG TABLET has been published 361 times since Sep 12, 2018, and over the history we have for it it has declined 43.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4012 per EA |
|---|---|
| All-time high | $2.4792 (Oct 10, 2018) |
| All-time low | $1.1052 (Jan 22, 2020) |
| 52-week high | $1.4012 |
| 52-week low | $1.2525 |
| Median price | $1.3719 |
| Average price | $1.5356 |
| Largest weekly change | +54.2% (Feb 17, 2021) |
| Weeks tracked | 361 |
| Tracking since | Sep 12, 2018 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamivudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE 300 MG TABLET, manufactured by Strides Pharma Inc., is $1.4012 per EA (NDC 64380071104), effective Sep 30, 2026.
How has the price of LAMIVUDINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE 300 MG TABLET has declined 43.5%. It has been tracked across 361 weekly CMS publications since Sep 12, 2018.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE 300 MG TABLET?
Since Sep 12, 2018, the NADAC for LAMIVUDINE 300 MG TABLET has ranged from a low of $1.1052 (Jan 22, 2020) to a high of $2.4792 (Oct 10, 2018), with a median of $1.3719 per EA.
Are there cheaper alternatives to LAMIVUDINE 300 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMIVUDINE 300 MG TABLET, is $1.3014 per EA — about 7% below LAMIVUDINE 300 MG TABLET.
Who manufactures LAMIVUDINE 300 MG TABLET?
LAMIVUDINE 300 MG TABLET (NDC 64380071104) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.